ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) — Active Not Recruiting • Phase II / Phase III • NCT05031780.
- Mitapivat tested in sickle cell patients to increase haemoglobin levels and reduce painful crisis episodes compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion. Conditions: Sickle Cell Disease Interventions: Mitapivat, Mitapivat-matching placebo, Mitapivat-matching placebo Lead Sponsor: Agios…